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Objectives: Adipokines are protein mediators first described as products of adipose tissue
regulating energy metabolism and appetite. Recently, adipokines have also been found to
modulate inflammation and smooth muscle cell responses. Therefore we investigated the as-
sociation of two adipokines, adiponectin and leptin, with the degree of emphysema, pulmo-
nary function, symptoms and glucocorticoid responsiveness in patients with COPD.
Methods: Plasma adiponectin and leptin levels, spirometry, body plethysmography and symp-
toms were measured in 43 male COPD patients with smoking history  20 pack-years, post
bronchodilator FEV1/FVC < 0.7 and pulmonary emphysema on HRCT. The measurements were
repeated in a subgroup of patients after 4 weeks’ treatment with inhaled fluticasone.
Results: In patients with COPD, plasma adiponectin levels correlated positively with airway
resistance (Raw) (r Z 0.362, p Z 0.019) and functional residual capacity (FRC) (r Z 0.355,
p Z 0.046). Furthermore, the baseline adiponectin concentration correlated negatively withof Respiratory Medicine, Tampere University Hospital, PL 2000, 33521 Tampere, Finland. Tel.: þ358 3
@uta.fi (S. Leivo-Korpela).
3 Elsevier Ltd. All rights reserved.
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Adiponectin and COPD 123the fluticasone induced changes in St George’s Respiratory questionnaire (SGRQ) symptom
score (rZ 0.413, pZ 0.040) and in FRC % pred (rZ 0.428, pZ 0.003), i.e. a higher base-
line plasma adiponectin level was associated with more pronounced alleviation of symptoms
and dynamic hyperinflation. Plasma leptin levels were not related to the measures of lung
function, symptoms or glucocorticoid responsiveness.
Conclusions: Plasma adiponectin levels were associated with peripheral airway obstruction
and dynamic hyperinflation in patients with COPD. A higher adiponectin level predicted more
favourable relief of symptoms and hyperinflation during glucocorticoid treatment. Adiponectin
may have a role in the COPD pathogenesis; it may also be a biomarker of disease severity and
treatment responses in this disease.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by a persistent airflow limitation with extrapulmo-
nary manifestations [1]. Inflammatory activity is present
not only in the lungs [2], but there is also a low-grade
systemic inflammation [3] associated with the develop-
ment of the comorbidities of COPD such as ischaemic heart
disease, osteoporosis, diabetes, cachexia and depression
[4e6]. It is uncertain whether the systemic inflammation in
COPD is a spillover of the inflammation present in the lungs
or if pulmonary manifestations are only one form of
expression of this systemic disease [5].
It is known that a subset of patients with COPD benefits
from inhaled glucocorticoid (GC) therapy, and GCs have
been shown to reduce the markers of systemic inflamma-
tion in COPD [7]. Unfortunately, current measurements of
lung function or pulmonary imaging cannot distinguish the
steroid responders from the non-responders, and therefore
novel systemic or local markers for steroid-sensitive
phenotype of COPD are critically needed.
Adipose tissue releases a variety of factors, also called
adipokines, which regulate energy metabolism and appe-
tite and, based on the recent studies, also inflammatory
responses [8]. The two best characterized adipokines are
adiponectin and leptin. Adiponectin improves insulin
sensitivity and, accordingly, plasma adiponectin levels are
decreased in obese individuals, especially in those with the
metabolic syndrome, type 2 diabetes and atherosclerosis
[9]. Adiponectin acts through two specific receptors (Adi-
poR1 and AdipoR2) and exerts a variety of anti-
inflammatory effects [10,11]. On the other hand, adipo-
nectin has also reported to enhance the production of pro-
inflammatory cytokines in airway epithelium [12] and to
mediate pro-inflammatory and tissue matrix degrading ef-
fects in arthritis [13e15].
Discovered in 1994 leptin is another important adipokine
[16]. Leptin controls appetite through its regulatory effects
in the central nervous system, and it has also a significant
role as an effector and regulator in inflammatory responses
[17]. Leptin increases the production of many pro-
inflammatory mediators and tissue matrix degrading
enzymes, and supports the Th1-type immune response
[18e20]. Circulating leptin levels directly correlate with
the amount of body fat [21] and leptin is linked to several
obesity associated inflammatory conditions like cardiovas-
cular [22] and rheumatic diseases [14].Both adiponectin and leptin are produced in the human
lung [12,23,24]. There is recent experimental data indi-
cating that they may also play a role in asthma and COPD
by modulating the inflammatory responses [25] and airway
smooth muscle cell functions [26]. Adipokines have also
been reported to be associated with fibrosing lung dis-
eases [27,28]. Furthermore, adipose-tissue related
inflammation has been proposed to represent a link con-
necting pulmonary damage with the systemic inflamma-
tion in COPD [3] but the mechanisms remain poorly
understood.
1Since adiponectin and leptin both seem to be involved
in the regulation of inflammation and smooth muscle
function as well as in the tissue matrix destruction, we
hypothesized that they may play a role in COPD. Therefore,
we investigated if plasma levels of adiponectin and leptin
would be associated with the degree of obstruction, hy-
perinflation and emphysema, with other markers of
inflammation, with the degree of symptoms and/or with
the response to inhaled glucocorticoids in patients with
COPD.Methods
Subjects and study design
We recruited forty-three steroid-naı¨ve male patients with
COPD among subjects referred from primary care for
diagnostic assessment to the Department of Respiratory
Medicine at Tampere University Hospital. COPD diagnosis
was based on GOLD strategy paper [1] and the inclusion
criteria were smoking history of at least 20 pack-years,
symptoms of COPD (cough, sputum production and dysp-
noea), post bronchodilator FEV1/FVC < 0.7, reversibility of
FVC or FEV1 induced by b2-agonist < 12% and 200 ml and
pulmonary emphysema visible on high-resolution computed
tomography (HRCT) of the lungs. None of the subjects had a
diagnosis or a clinical history of asthma. Forty-one age-
matched non-smoking healthy males with normal lung
function served as controls.
Spirometry and body plethysmography were measured,
high-resolution computed tomography (HRCT) of the lungs
was performed and symptoms were scored with the St
George’s Respiratory Questionnaire (SGRQ) in patients with
COPD. A venous blood sample was drawn in both groups.
The same measurements excluding HRCT were repeated in
Table 1 Characteristics of the subjects.
COPD Controls p-Value
N 43 41
Age (yrs) 59.5  1.2 62.5  1.0 0.057
BMI (kg/m2) 25.8  0.6 26.7  0.6 0.332
FEV1 (% pred) 53  2 a e
Raw (% pred) 213  14 N.A. e
FRC (% pred) 123  5 N.A. e
TLC (% pred) 108  2 N.A. e
MPO (ng/ml) 158.9  11.6 139.6  4.9 0.131
IL-6 (pg/ml) 1.5  0.2 1.5  0.2 0.888
MMP-9 (ng/ml) 40.6  2.7 33.9  2.0 0.048
Adiponectinb (ng/ml) 3034  328 2538  191 0.210
Leptinb (ng/ml) 7.5  0.9 7.1  1.0 0.703
Values are presented as mean  SEM.
N.A., not analyzed.
BMI, body mass index; FEV1, forced expiratory volume in 1 s;
Raw, airway resistance; FRC, functional residual capacity; TLC,
total lung capacity; MPO, myeloperoxidase; IL-6, interleukin 6;
MMP-9, matrix metalloproteinase 9.
a Normal in every subject.
b Because distributions of adiponectin and leptin were
skewed, log-transformed values were used in the statistical
analysis.
124 S. Leivo-Korpela et al.twenty-seven patients with COPD after 4 weeks of treat-
ment with inhaled fluticasone propionate (Flixotide Diskus
500 mg b.i.d.; GlaxoSmithKline, Ware, UK).
Adipokines and inflammatory markers
Plasma concentrations of adiponectin, leptin, myeloper-
oxidase (MPO), interleukin 6 (IL-6) and matrix metal-
loproteinase 9 (MMP-9) were determined by
enzymeimmunoassay by using the following reagents: adi-
ponectin, leptin and MMP-9: R&D Systems Europe Ltd,
Abingdon, UK; MPO: Hycult Biotechnology, Uden,
Netherlands; and IL-6: Sanquin, Amsterdam, Netherlands.
The detection limits and inter-assay coefficients of varia-
tion, were 31.3 pg/ml and 6.7% for adiponectin, 15.6 pg/ml
and 4.5% for leptin, 0.4 ng/ml and 8.7% for MPO, 0.3 pg/ml
and 7.6% for IL-6, and 7.8 pg/ml and 6.0% for MMP-9.
Lung function and HRCT
Forced vital capacity (FVC) and forced expiratory volume in
1 s (FEV1) were measured with the Vmax 20 C spirometer
(Sensor-Medics, Yorba Linda, CA, USA) before and after
400 mg of inhaled salbutamol. Airway resistance (Raw) and
functional residual capacity (FRC) were measured with
Autobox 6200 body plethysmography (Sensor-Medics, Yorba
Linda, CA, USA).
In the HRCT examinations (Siemens Somatom Plus 4,
Siemens Medical, Erlangen, Germany), a section thickness
of 1 mm was used with a 10-mm inter-slice spacing at
140 kV and 206 mA s. The subjects were lying in the supine
position and performing full inspiration. The HRCT images
were scored according to a consensus by two experienced
thoracic radiologists (RJ and LK) blinded to the medical
information of the patients.
The extent of emphysema was estimated visually to the
nearest 5% on each image section excluding the two most
cranial and caudal images, as described by Desai and col-
leagues [29]. The mean value of emphysema percent on all
image sections was taken as the final emphysema score for
each subject. In the evaluation of the airway wall thickness,
the external diameter (D) and the luminal diameter (L) of
the right upper lobe bronchus were measured in each sub-
ject. Only images showing the bronchus as a cross-section
without an angle were selected. Airway wall thickness (T )
was calculated as (D L)/2. The thickness-to-diameter ratio
(TDR) and the percentage wall area (PWA) were calculated
as TDRZT/D, and PWAZðD=2Þ2p ðL=2Þ2p=ðD=2Þ2p 100%
[30]. TDR and PWA were used in statistical analysis.
Symptom scoring
The subjects filled in the Finnish translation of the St
George’s Respiratory Questionnaire (SGRQ) containing
questions and scoring on three aspects of the disease
(symptom frequency and severity, activities that cause or
are limited by breathlessness, and the impact of the dis-
ease on social functioning including psychological distur-
bances resulting from the disease) to obtain a total score.
The scale has a range from 0 to 100, with higher scores
representing more severe disease.Statistics
The distributions of both adiponectin and leptin levels were
skewed but they became normal after log-transformation,
which was used in the statistical analyses. t-Test was used
to examine differences between healthy controls and pa-
tients with COPD. To test if adiponectin or leptin correlate
with markers of disease severity, partial correlation con-
trolling for body mass index (BMI) was used as both log-
adiponectin and log-leptin correlated with BMI. Changes
in plasma levels of adipokines and other measures during
fluticasone treatment were analyzed with paired t-test.
The results are presented as mean  SEM. A p-value < 0.05
was considered as significant. SPSS 19 software (SPSS Inc.,
Chicago, Illinois, USA) was used in the statistical analysis.
Ethics
The study was approved by the ethics committee of Tam-
pere University Hospital, Tampere, Finland and complies
with the declaration of Helsinki. All subjects provided their
written informed consent.
Results
The subject characteristics are shown in Table 1. There
were no differences with respect to the age or BMI between
the patients with COPD and the controls but, as expected,
plasma MMP-9 levels were higher in those individuals with
emphysematous COPD. The adiponectin level correlated
negatively with BMI (r Z 0.588, p < 0.001), while there
was a positive correlation between leptin concentration
and BMI (rZ 0.700, p < 0.001), as expected. There were no
statistically significant differences in plasma adiponectin
Table 3 Adipokines and other parameters before and
after fluticasone treatment in COPD patients.
Before treatment After treatment p-Value
Adiponectina
(ng/ml)
3594  486 3460  457 0.598
Leptina (ng/ml) 6.0  1.0 7.1  1.2 0.018
FEV1 (% pred) 53  3 56  3 0.288
Raw (% pred) 214  19 210  16 0.656
FRC (% pred) 123  6 121  6 0.467
MPO (ng/ml) 166  16 171  17 0.768
IL-6 (pg/ml) 1.62  0.29 1.67  0.26 0.747
MMP-9 (ng/ml) 39.1  3.5 44.9  4.2 0.268
SGRQ total score 36.4  3.1 30.8  3.1 0.015
SGRQ symptom
score
55.2  4.3 38.0  4.5 <0.001
Values are presented as mean  SEM, n Z 27.
FEV1, forced expiratory volume in 1 s; Raw, airway resistance;
FRC, functional residual capacity; MPO, myeloperoxidase; IL-6,
interleukin 6; MMP-9, matrix metalloproteinase 9; SGRQ, St
George’s Respiratory Questionnaire.
Statistically significant p-values (p < 0.05) are bolded.
a Because distributions of adiponectin and leptin were
skewed, log-transformed values were used in the statistical
analysis.
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trols, or between ex-smokers (nZ 10) and current smokers
(n Z 33) in the COPD group.
In the COPD patients, body plethysmography was carried
out to evaluate small airway obstruction (measured as
airway resistance, Raw) and dynamic hyperinflation
(measured as functional residual capacity, FRC). Interest-
ingly, adiponectin levels correlated positively with airway
resistance (Raw % predicted, rZ 0.362, pZ 0.019, Table 2)
and functional residual capacity (FRC % predicted,
r Z 0.355, p Z 0.046, Table 2), i.e. high plasma adipo-
nectin concentrations were associated with peripheral
obstruction and hyperinflation. Neither adiponectin nor
leptin levels correlated with FEV1 or FEV1/FVC, with the
inflammatory markers measured in plasma, with the degree
of emphysema or airway wall thickness on HRCT or with
SGRQ scores at baseline.
The effect of 4 weeks’ fluticasone treatment on the adi-
pokine levels and other parameters are shown in Table 3. St
George’s Respiratory Questionnaire (SGRQ) total and symp-
tom scores decreased and leptin levels increased during the
treatment, but there were no other significant changes.
Interestingly, the baseline adiponectin level correlated
negatively with fluticasone induced changes in SGRQ total
score (r Z 0.410, p Z 0.042), SGRQ symptom score
(rZ 0.413, pZ 0.040) and FRC % predicted (rZ 0.428,
p Z 0.003), indicating that high baseline adiponectin level
was associated with favourable relief of symptoms and hy-
perinflation in response to fluticasone treatment.
Discussion
The main findings of the present study were that high
plasma adiponectin levels were associated with obstructionTable 2 BMI-adjusted partial correlations between adi-
ponectin and leptin and other parameters in COPD patients
(n Z 43).
Adiponectina Leptina
FEV1 (% pred) r Z 0.058
p Z 0.717
r Z 0.000
p Z 0.999
Raw (% pred) r Z 0.362
p Z 0.019
r Z 0.089
p Z 0.576
FRC (% pred) r Z 0.355
p Z 0.046
r Z 0.225
p Z 0.216
Emphysema percentage (%) r Z 0.208
p Z 0.186
r Z 0.217
p Z 0.167
MPO r Z 0.117
p Z 0.483
r Z 0.160
p Z 0.338
IL-6 r Z 0.012
p Z 0.942
r Z 0.172
p Z 0.276
MMP-9 r Z 0.121
p Z 0.463
r Z 0.029
p Z 0.860
FEV1, forced expiratory volume in 1 s; Raw, airway resistance;
FRC, functional residual capacity; MPO, myeloperoxidase; IL-6,
interleukin 6; MMP-9, matrix metalloproteinase 9.
Statistically significant p-values (p < 0.05) are bolded.
a Because distributions of adiponectin and leptin were
skewed, log-transformed values were used in the statistical
analysis.in peripheral airways and predicted a favourable effect of
inhaled fluticasone treatment on both symptoms and dy-
namic hyperinflation in patients with COPD. This indicates
that adiponectin may have a role in the pathogenesis of
COPD and in addition, it may serve as a biomarker of dis-
ease severity.
Originally, adipose-tissue derived adipokines were found
to regulate energy metabolism and be associated with the
chronic low-grade inflammation present in obesity-related
metabolic disturbances and inflammatory diseases [11,31].
More recently, adiponectin and leptin have also been linked
with inflammatory lung diseases like asthma and COPD [25].
The majority of the studies have hinted that high circulating
leptin and low adiponectin levels seem to be associated with
asthma independently of the presence of obesity [25,32].
Accordingly, we have recently found that increased leptin
levels were associated with more severe asthma also in non-
obese patients [33]. The data on adiponectin and leptin
levels in human COPD are less conclusive [25]. Breyer et al.
hypothesized that adipokine metabolism is altered in pa-
tients suffering fromCOPD, particularly inwomen [34]. Some
human studies have demonstrated higher plasma or serum
adiponectin concentrations also in male patients with COPD
when they are compared to healthy controls [34e37]. Caro-
lan et al. found increased levels of adiponectin especially in
subjectswith very severeCOPD [38]. In thepresent study, the
mean adiponectin level was somewhat higher in COPD pa-
tients than in healthy controls although the difference was
not statistically significant. There was variation in the adi-
ponectin levels in COPD patients, and interestingly, higher
adiponectin levels were associated with more severe airway
obstruction and hyperinflation in patients with COPD.
It is thought that there are many causes for the airway
obstruction in COPD such as mucosal oedema, contraction of
the airway smooth muscle, small airway fibrosis and loss of
126 S. Leivo-Korpela et al.parenchymal support to small airways due to emphysema
[2]. In the present study, we observed that plasma adipo-
nectin levels correlated with Raw and FRC but not with FEV1
and FEV1/FVC. This is interesting, as FEV1 and FEV1/FVC are
mostly reflecting obstruction in the larger airways and these
parameters are not very sensitive to changes occurring in the
small airways. Furthermore, in cases of severe small airway
obstruction and airway closure during exhalation causing
dynamic hyperinflation, FCV reductions in addition to FEV1
and the ratio FEV1/FVC may not reflect the severity of small
airway obstruction. Raw is a more sensitive measure of small
airway obstruction than FEV1 or FEV1/FVC, and FRC is
believed to be a good marker of dynamic hyperinflation in
COPD [39]. Thus, our results suggest that adiponectinmay be
more closely related to peripheral than central airway
obstruction in COPD. This is in line with the earlier results of
Tomoda and colleagues who reported that the plasma adi-
ponectin level correlated with hyperinflation but not with
FEV1 in their sample of COPD patients [35].
The relation between adiponectin levels in plasma and
small airway obstruction suggests that adiponectin may be
a marker or even a mediator of parenchymal inflammation
and the tissue destruction present in emphysematous
COPD, which then leads to small airway obstruction and
hyperinflation. Our results are supported by the data in a
cohort of COPDGene study, in which Carolan et al. found an
association between plasma adiponectin and CT-assessed
emphysema in patients with COPD [38]. Interestingly, the
degenerative cartilage changes seen in (osteo)arthritis
seem to display similarities with tissue matrix degrading
events leading to pulmonary emphysema in COPD. Adipo-
nectin has been reported to contribute to cartilage matrix
destruction in arthritis by inducing the production of the
same pro-inflammatory cytokines and degrading metal-
loproteinase enzymes that are also involved in COPD and
emphysema [2,14]. In addition, adiponectin may have a
direct effect on airway function, as human airway smooth
muscle cells express adiponectin receptors [26] and adi-
ponectin is known to increase contractility in smooth
muscle cells [40]. Thus, it may be that increased levels of
circulating adiponectin enhance the contractility of airway
smooth muscle and are involved in inducing the airway
obstruction, and also contribute to the inflammation and
tissue destruction which is evident in COPD.
We also found that high baseline levels of adiponectin
predicted good symptom relief and alleviation of hyperin-
flation in response to inhaled fluticasone treatment. This
finding also indicates that there is a relationship between
lung inflammation and the circulating adiponectin levels
and further suggests that adiponectin is related to the
steroid-sensitive phenotype in COPD. On the other hand,
specific inhibition of the adiponectin induced smooth
muscle contraction might be one of the mechanisms
through which glucocorticoids act to alleviate small airway
obstruction and the symptoms in COPD. This is supported by
the fact that glucocorticoids can inhibit the expression of
adiponectin receptors (AdipoR1 and AdipoR2) as shown in
rat [41] and human muscle cells [42]. Therefore it may be
that the contractile effect of adiponectin on airway smooth
muscle is alleviated if adiponectin receptor density is
reduced during glucocorticoid treatment. In addition, glu-
cocorticoids have been shown to decrease adiponectinexpression under some conditions [41] and this might also
be a potential mechanism linking adiponectin and the
response to steroid treatment. However, most of the
studies [43e45] have reported that glucocorticoids, deliv-
ered either orally or by inhalation, do not alter plasma
levels of adiponectin. This is in line with our present finding
that fluticasone treatment had no effect on the circulating
adiponectin concentrations.
Based on data from animal studies, adiponectin has also
been proposed to exert a protective role against emphy-
sema, as adiponectin deficiency has been reported to lead
to increased levels of two pro-inflammatory mediators,
TNF-a and MMP-12, and to an emphysema-like phenotype in
the mouse lung [46,47]. In addition, exposure to tobacco
smoke has been reported to reduce the expression of adi-
ponectin in both mice [48] and humans [12], but adipo-
nectin is highly expressed in the lungs of patients with the
emphysematous form of COPD [12]. However, we observed
no correlation between the degree of emphysema on HRCT
and plasma levels of adiponectin in these subjects with
emphysematous COPD. Furthermore, there was no differ-
ence in plasma levels of adiponectin between healthy non-
smoking controls and patients with emphysematous COPD.
This is in line with the results of the large ECLIPSE study
[49], although there are also reports of increased serum
levels of adiponectin in COPD [34e38].
We detected no difference in plasma levels of leptin
between controls and subjects with emphysematous COPD.
Previous data on leptin is controversial, as some studies
have shown increased [50], others decreased [51,52] and
some unchanged [34,36] circulating leptin levels in patients
with COPD. These differences are most likely attributable
to the heterogeneity of the COPD patient populations and,
may also be affected by the gender-dependent differences
in adipokine metabolism. As in the present study, Kirdar
et al. found no significant differences in plasma leptin
levels between male patients with stable COPD and healthy
controls [36]. In the study of Breyer et al., leptin levels did
not differ between subjects with COPD and healthy con-
trols, but in both groups, the leptin levels were higher in
females than in males [34]. In addition, leptin levels
correlated with CRP, IL-6 and fibrinogen only in females but
not in males with COPD [34]. This is evidence of an
important gender-related difference in leptin metabolism
and it may be explained by different proportions of adipose
tissue of the body composition and possibly also partly by
an interesting finding indicating that androgens can inhibit
leptin secretion whereas it is stimulated by oestradiol [53].
Leptin may also be associated with some features or
comorbidities of COPD. In fact, alterations in leptin levels
are often associated with COPD exacerbations [54,55].
Leptin has been shown to stimulate the production of
vascular endothelial growth factor (VEGF) in human airway
smooth muscle in vitro and leptin could therefore affect
angiogenesis and promote airway remodelling in COPD [26].
On the other hand, leptin does not evoke contractile re-
sponses in human airway smooth muscle cells [56], and this
is in line with our findings that the leptin level did not
correlate with the markers of airway obstruction. Inter-
estingly, we found that treatment with inhaled fluticasone
increased plasma levels of leptin in the COPD patients.
Glucocorticoids have been reported to stimulate leptin
Adiponectin and COPD 127expression in adipose tissue [57] and to increase plasma
leptin levels in patients with polymyalgia rheumatica [58].
This may be attributable to a direct effect of glucocorti-
coids on leptin gene expression, as the glucocorticoid
responsive element (GRE) has been identified in the leptin
gene promoter [59].
In the present study, high plasma levels of adiponectin
were associated with peripheral airway obstruction and
dynamic hyperinflation in patients with COPD. Further-
more, higher plasma levels of adiponectin also predicted
more favourable relief of symptoms and hyperinflation
during glucocorticoid treatment, supporting the experi-
mental data that adiponectin is a pro-inflammatory medi-
ator able to induce tissue matrix degradation and to evoke
smooth muscle contraction. However, further studies will
be needed to confirm the role of adiponectin in the path-
ogenesis of COPD and whether it is useful as a marker of the
steroid-sensitive phenotype in this disease.Conflict of interest
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